CONMED CORP (CNMD) Fundamental Analysis & Valuation

NYSE:CNMD • US2074101013

Current stock price

34.54 USD
+0.46 (+1.35%)
At close:
34.54 USD
0 (0%)
After Hours:

This CNMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. CNMD Profitability Analysis

1.1 Basic Checks

  • In the past year CNMD was profitable.
  • In the past year CNMD had a positive cash flow from operations.
  • CNMD had positive earnings in 4 of the past 5 years.
  • In the past 5 years CNMD always reported a positive cash flow from operatings.
CNMD Yearly Net Income VS EBIT VS OCF VS FCFCNMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 2.02%, CNMD is in the better half of the industry, outperforming 73.40% of the companies in the same industry.
  • CNMD's Return On Equity of 4.55% is fine compared to the rest of the industry. CNMD outperforms 75.53% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 4.23%, CNMD is in the better half of the industry, outperforming 72.87% of the companies in the same industry.
  • CNMD had an Average Return On Invested Capital over the past 3 years of 5.32%. This is below the industry average of 9.40%.
Industry RankSector Rank
ROA 2.02%
ROE 4.55%
ROIC 4.23%
ROA(3y)3.52%
ROA(5y)2.12%
ROE(3y)8.68%
ROE(5y)4.64%
ROIC(3y)5.32%
ROIC(5y)4.74%
CNMD Yearly ROA, ROE, ROICCNMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 -10

1.3 Margins

  • Looking at the Profit Margin, with a value of 3.42%, CNMD is in the better half of the industry, outperforming 74.47% of the companies in the same industry.
  • In the last couple of years the Profit Margin of CNMD has grown nicely.
  • CNMD has a better Operating Margin (8.39%) than 75.53% of its industry peers.
  • In the last couple of years the Operating Margin of CNMD has grown nicely.
  • The Gross Margin of CNMD (54.59%) is comparable to the rest of the industry.
  • CNMD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.39%
PM (TTM) 3.42%
GM 54.59%
OM growth 3Y4.64%
OM growth 5Y1.5%
PM growth 3YN/A
PM growth 5Y25.45%
GM growth 3Y-0.47%
GM growth 5Y-0.15%
CNMD Yearly Profit, Operating, Gross MarginsCNMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

4

2. CNMD Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CNMD is destroying value.
  • Compared to 1 year ago, CNMD has more shares outstanding
  • The number of shares outstanding for CNMD has been increased compared to 5 years ago.
  • The debt/assets ratio for CNMD has been reduced compared to a year ago.
CNMD Yearly Shares OutstandingCNMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
CNMD Yearly Total Debt VS Total AssetsCNMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • CNMD has an Altman-Z score of 1.79. This is a bad value and indicates that CNMD is not financially healthy and even has some risk of bankruptcy.
  • CNMD has a Altman-Z score of 1.79. This is comparable to the rest of the industry: CNMD outperforms 55.85% of its industry peers.
  • CNMD has a debt to FCF ratio of 5.53. This is a neutral value as CNMD would need 5.53 years to pay back of all of its debts.
  • The Debt to FCF ratio of CNMD (5.53) is better than 75.00% of its industry peers.
  • A Debt/Equity ratio of 0.81 indicates that CNMD is somewhat dependend on debt financing.
  • The Debt to Equity ratio of CNMD (0.81) is worse than 72.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF 5.53
Altman-Z 1.79
ROIC/WACC0.72
WACC5.91%
CNMD Yearly LT Debt VS Equity VS FCFCNMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.3 Liquidity

  • CNMD has a Current Ratio of 2.14. This indicates that CNMD is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.14, CNMD is in line with its industry, outperforming 40.96% of the companies in the same industry.
  • CNMD has a Quick Ratio of 1.01. This is a normal value and indicates that CNMD is financially healthy and should not expect problems in meeting its short term obligations.
  • CNMD has a Quick ratio of 1.01. This is amonst the worse of the industry: CNMD underperforms 80.32% of its industry peers.
Industry RankSector Rank
Current Ratio 2.14
Quick Ratio 1.01
CNMD Yearly Current Assets VS Current LiabilitesCNMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

4

3. CNMD Growth Analysis

3.1 Past

  • CNMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.82%, which is quite good.
  • The Earnings Per Share has been growing by 16.37% on average over the past years. This is quite good.
  • CNMD shows a small growth in Revenue. In the last year, the Revenue has grown by 5.18%.
  • CNMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.77% yearly.
EPS 1Y (TTM)10.82%
EPS 3Y20.27%
EPS 5Y16.37%
EPS Q2Q%6.72%
Revenue 1Y (TTM)5.18%
Revenue growth 3Y9.55%
Revenue growth 5Y9.77%
Sales Q2Q%7.88%

3.2 Future

  • Based on estimates for the next years, CNMD will show a small growth in Earnings Per Share. The EPS will grow by 7.09% on average per year.
  • The Revenue is expected to grow by 3.55% on average over the next years.
EPS Next Y-3.63%
EPS Next 2Y4.41%
EPS Next 3Y7.09%
EPS Next 5YN/A
Revenue Next Year-0.72%
Revenue Next 2Y2.34%
Revenue Next 3Y3.55%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CNMD Yearly Revenue VS EstimatesCNMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B
CNMD Yearly EPS VS EstimatesCNMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4 5

8

4. CNMD Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 7.49, the valuation of CNMD can be described as very cheap.
  • CNMD's Price/Earnings ratio is rather cheap when compared to the industry. CNMD is cheaper than 94.68% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of CNMD to the average of the S&P500 Index (26.21), we can say CNMD is valued rather cheaply.
  • The Price/Forward Earnings ratio is 7.77, which indicates a rather cheap valuation of CNMD.
  • 96.81% of the companies in the same industry are more expensive than CNMD, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 23.10. CNMD is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 7.49
Fwd PE 7.77
CNMD Price Earnings VS Forward Price EarningsCNMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CNMD is valued cheaper than 92.02% of the companies in the same industry.
  • 98.40% of the companies in the same industry are more expensive than CNMD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.06
EV/EBITDA 9.8
CNMD Per share dataCNMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30 40

4.3 Compensation for Growth

  • CNMD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.46
EPS Next 2Y4.41%
EPS Next 3Y7.09%

6

5. CNMD Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 2.31%, CNMD has a reasonable but not impressive dividend return.
  • CNMD's Dividend Yield is rather good when compared to the industry average which is at 0.25. CNMD pays more dividend than 95.74% of the companies in the same industry.
  • CNMD's Dividend Yield is a higher than the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 2.31%

5.2 History

  • The dividend of CNMD has a limited annual growth rate of 0.10%.
  • CNMD has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)0.1%
Div Incr Years0
Div Non Decr Years0
CNMD Yearly Dividends per shareCNMD Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

  • CNMD pays out 52.59% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • The dividend of CNMD is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.59%
EPS Next 2Y4.41%
EPS Next 3Y7.09%
CNMD Yearly Income VS Free CF VS DividendCNMD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M
CNMD Dividend Payout.CNMD Dividend Payout, showing the Payout Ratio.CNMD Dividend Payout.PayoutRetained Earnings

CNMD Fundamentals: All Metrics, Ratios and Statistics

CONMED CORP

NYSE:CNMD (4/7/2026, 9:27:10 PM)

After market: 34.54 0 (0%)

34.54

+0.46 (+1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-28
Earnings (Next)04-29
Inst Owners112.69%
Inst Owner Change0%
Ins Owners0.28%
Ins Owner Change1.42%
Market Cap1.06B
Revenue(TTM)1.37B
Net Income(TTM)47.05M
Analysts50.91
Price Target45.08 (30.52%)
Short Float %7.35%
Short Ratio4.24
Dividend
Industry RankSector Rank
Dividend Yield 2.31%
Yearly Dividend0.8
Dividend Growth(5Y)0.1%
DP52.59%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.3%
Min EPS beat(2)0.66%
Max EPS beat(2)5.94%
EPS beat(4)4
Avg EPS beat(4)5.44%
Min EPS beat(4)0.37%
Max EPS beat(4)14.78%
EPS beat(8)8
Avg EPS beat(8)5.62%
EPS beat(12)11
Avg EPS beat(12)4.63%
EPS beat(16)13
Avg EPS beat(16)0.77%
Revenue beat(2)0
Avg Revenue beat(2)-0.64%
Min Revenue beat(2)-1.03%
Max Revenue beat(2)-0.25%
Revenue beat(4)1
Avg Revenue beat(4)-0.38%
Min Revenue beat(4)-1.03%
Max Revenue beat(4)0.51%
Revenue beat(8)1
Avg Revenue beat(8)-0.84%
Revenue beat(12)3
Avg Revenue beat(12)-0.05%
Revenue beat(16)4
Avg Revenue beat(16)-1.46%
PT rev (1m)-6.75%
PT rev (3m)-8.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.72%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.35%
Valuation
Industry RankSector Rank
PE 7.49
Fwd PE 7.77
P/S 0.77
P/FCF 7.06
P/OCF 6.24
P/B 1.03
P/tB N/A
EV/EBITDA 9.8
EPS(TTM)4.61
EY13.35%
EPS(NY)4.44
Fwd EY12.86%
FCF(TTM)4.89
FCFY14.17%
OCF(TTM)5.54
OCFY16.03%
SpS44.59
BVpS33.51
TBVpS-11.55
PEG (NY)N/A
PEG (5Y)0.46
Graham Number58.96
Profitability
Industry RankSector Rank
ROA 2.02%
ROE 4.55%
ROCE 5.74%
ROIC 4.23%
ROICexc 4.31%
ROICexgc 14.63%
OM 8.39%
PM (TTM) 3.42%
GM 54.59%
FCFM 10.98%
ROA(3y)3.52%
ROA(5y)2.12%
ROE(3y)8.68%
ROE(5y)4.64%
ROIC(3y)5.32%
ROIC(5y)4.74%
ROICexc(3y)5.4%
ROICexc(5y)4.81%
ROICexgc(3y)19.18%
ROICexgc(5y)17.21%
ROCE(3y)7.22%
ROCE(5y)6.44%
ROICexgc growth 3Y7.2%
ROICexgc growth 5Y4.14%
ROICexc growth 3Y14.69%
ROICexc growth 5Y5.99%
OM growth 3Y4.64%
OM growth 5Y1.5%
PM growth 3YN/A
PM growth 5Y25.45%
GM growth 3Y-0.47%
GM growth 5Y-0.15%
F-Score5
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF 5.53
Debt/EBITDA 4.4
Cap/Depr 26.66%
Cap/Sales 1.44%
Interest Coverage 4.54
Cash Conversion 90.02%
Profit Quality 320.65%
Current Ratio 2.14
Quick Ratio 1.01
Altman-Z 1.79
F-Score5
WACC5.91%
ROIC/WACC0.72
Cap/Depr(3y)23.78%
Cap/Depr(5y)24.75%
Cap/Sales(3y)1.32%
Cap/Sales(5y)1.51%
Profit Quality(3y)200.6%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.82%
EPS 3Y20.27%
EPS 5Y16.37%
EPS Q2Q%6.72%
EPS Next Y-3.63%
EPS Next 2Y4.41%
EPS Next 3Y7.09%
EPS Next 5YN/A
Revenue 1Y (TTM)5.18%
Revenue growth 3Y9.55%
Revenue growth 5Y9.77%
Sales Q2Q%7.88%
Revenue Next Year-0.72%
Revenue Next 2Y2.34%
Revenue Next 3Y3.55%
Revenue Next 5YN/A
EBIT growth 1Y-44.98%
EBIT growth 3Y14.64%
EBIT growth 5Y11.42%
EBIT Next Year26.75%
EBIT Next 3Y14.3%
EBIT Next 5YN/A
FCF growth 1Y-1.95%
FCF growth 3Y135.18%
FCF growth 5Y23.98%
OCF growth 1Y2.23%
OCF growth 3Y72.25%
OCF growth 5Y21.49%

CONMED CORP / CNMD Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CONMED CORP (CNMD) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CNMD.


Can you provide the valuation status for CONMED CORP?

ChartMill assigns a valuation rating of 8 / 10 to CONMED CORP (CNMD). This can be considered as Undervalued.


Can you provide the profitability details for CONMED CORP?

CONMED CORP (CNMD) has a profitability rating of 6 / 10.


How financially healthy is CONMED CORP?

The financial health rating of CONMED CORP (CNMD) is 4 / 10.


How sustainable is the dividend of CONMED CORP (CNMD) stock?

The dividend rating of CONMED CORP (CNMD) is 6 / 10 and the dividend payout ratio is 52.59%.